The results from the study suggested that amphetamine-injected C57BL/6 mice showed a dose dependent reduction in hyperactivity when administered CM-182.
Currently, the company is planning to conduct further trials on CM-182.
Curemark Research and Development director James Szigethy said their findings in the C57BL/6 mouse model with amphetamine induced hyperactivity are consistent with findings of other psychotropic medications utilized to treat hyperactivity, but without the sedating effects
Curemark CEO Joan Fallon said their results demonstrate that their novel compound indeed shows promise for the treatment of hyperactivity without sedation.